moderate - Healthcare segment (50% of revenue) is relatively recession-resistant as hospitals face operational pressures regardless of economic conditions, though elective procedure volumes can decline in downturns. Education segment is counter-cyclical in some respects (universities seek efficiency during budget constraints) but faces long-term enrollment headwinds. Business advisory is pro-cyclical, with corporate transformation and M&A-related work declining in recessions. Overall, the mix provides partial insulation from severe economic downturns compared to pure corporate consulting firms.

Rising interest rates have mixed effects: (1) Negative impact on valuation multiples as investors discount future cash flows at higher rates, particularly affecting growth-oriented professional services stocks trading at 15-20x EBITDA. (2) Indirect negative impact as higher rates pressure hospital systems' capital budgets and university endowment returns, potentially delaying discretionary consulting projects. (3) Positive impact through increased restructuring and turnaround advisory demand as leveraged clients face refinancing challenges. The company's $200M debt load (1.3x D/E) creates modest interest expense sensitivity, though most debt is fixed-rate term loans.

value with growth characteristics - trades at 14x EBITDA (discount to pure-play tech consultancies at 20x+) but offers 9% revenue growth and 21% ROE. Attracts investors seeking exposure to healthcare services secular growth with lower volatility than hospital operators. Recent 86% net income growth and 96% EPS growth (likely reflecting margin recovery post-pandemic or one-time items) appeals to momentum investors, though sustainability requires verification. The 8.3% FCF yield attracts value-oriented funds seeking cash-generative businesses with M&A optionality.